Video above: Legal challenges following the Dobbs Supreme Court decision
This week, the Food and Drug Administration (FDA) approved a new generic version of the abortion drug mifepristone, stirring discontent among conservative groups.
Evita Solutions received a notification from the FDA on Tuesday, stating that their abbreviated new drug application satisfied the required criteria and was given the green light.
The FDA’s message indicated, “We have determined your Mifepristone Tablets, 200 mg to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Mifeprex (mifepristone) tablets, 200 mg, produced by Danco Laboratories.”
Originally approved by the FDA in 2000, mifepristone is used alongside misoprostol for medical abortions, which represent about two-thirds of abortion procedures in the U.S.
Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary recently mentioned that the agency might reconsider the Risk Evaluation and Mitigation Strategy requirements, referencing “recent studies raising concerns about the safety of mifepristone as currently administered.”
This action drew outcry from anti-abortion conservative voices.
Marjorie Dannenfelser, president of the anti-abortion group Susan B. Anthony Pro-Life America, called the decision “unconscionable.”
Dannenfelser expressed concerns, saying, “These dangerous drugs take the lives of unborn children, place women and underage girls at serious risk, empower abusers, and trample the pro-life laws enacted by states across the nation,” and reiterated calls for the previous administration to roll back the current policy that permits the mailing of abortion pills.
Sen. Josh Hawley (R-Mo.) echoed these calls, writing on the social media platform X, “This is shocking. FDA has just approved ANOTHER chemical abortion drug, when the evidence shows chemical abortion drugs are dangerous and even deadly for the mother. And of course 100% lethal to the child.”
The Hill has reached out to Evita Solutions for comment. On the company’s website, it stated its new FDA-approved product would be “coming soon.”
“Medical abortion care is rife with medically unnecessary restrictions and social stigma in the United States. As a result, many people who choose to end a pregnancy may struggle to get the necessary care they need,” the website states.
